이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

기증자 줄기 세포 이식을 받는 혈액암 환자의 이식편대숙주병 예방을 위한 인간 리소자임 산양유

2026년 11월 9일 업데이트: City of Hope Medical Center

표준 골수 파괴 동종 조혈 줄기 세포 이식 수혜자에서 인간 리소자임 염소 우유의 무작위 파일럿 연구

This phase I trial studies the side effects of human lysozyme goat milk in preventing graft versus host disease in patients with blood cancer undergoing a donor stem cell transplant. Sometimes the transplanted cells from a donor can cause an immune response against the body's own normal cells (call graft versus host disease). The goat milk in the study is from goats that have been genetically engineered to produce human lysozyme in the milk. Human lysozyme is a natural enzyme found in human milk and acts as an antimicrobial. Lysozyme is key to the digestive health of breast-fed human infants, since it helps the growth of beneficial gut bacteria and reduces the growth of bacteria that causes diarrhea and intestinal disease. Giving human lysozyme goat milk may reduce the rate of graft versus host disease in blood cancer patients undergoing a donor stem cell transplant.

연구 개요

상세 설명

PRIMARY OBJECTIVES:

I. To evaluate the safety and feasibility of human lysozyme goat milk (hLZ) treatment by assessing:

Ia: Type, frequency, severity, attribution, time course and duration of adverse events, including diarrhea, bloodstream/intestinal infections.

Ib. Patients' ability to drink the specified volume (250 ml 3 x/day) of hLZ during the treatment period.

SECONDARY OBJECTIVES:

I. To compare the incidence and severity of adverse events (AE) among hLZ-treated and untreated patients, including diarrhea, bloodstream infections and intestinal infections.

II. To obtain preliminary estimates of gut microbiome diversity, as assessed by the Simpson Index, in hLZ-treated/untreated patients.

III. To compare gut microbiome diversity among hLZ-treated/untreated patients. IV. To obtain a preliminary estimate of the possible association between gut microbiome diversity and bloodstream infections.

V. To obtain a preliminary estimate of the possible association between gut microbiome diversity and acute graft versus host disease (GVHD) cumulative incidence, including time to onset.

VI. To characterize and compare GVHD inflammatory biomarkers (presence, level) among hLZ-treated and untreated patients.

VII. To characterize and compare urinary uindoxyl sulfate, tryptophan and kynurenine levels between hLZ-treated and untreated patients.

IX. To obtain a preliminary estimate of gut microbiome diversity and calorie intake.

X. To estimate overall survival (OS) cumulative incidence (CI) chronic GVHD of relapse/progression, and non-relapse mortality (NRM) at 100 days (excluding chronic GVHD), 6 months, 1 year and 2 years.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP A:

CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2, undergo fractionated total body irradiation (FTBI) on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per City of Hope (COH) standard operating procedure (SOP) in the absence of disease progression or unacceptable toxicity.

HLZ: Patients receive human lysozyme goat milk orally (PO) three times daily (TID) on days -8 to 28 in the absence of disease progression or unacceptable toxicity.

TRANSPLANT: Patients undergo stem cell transplant on day 0.

GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity.

GROUP B:

CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2 per COH SOP, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.

TRANSPLANT: Patients undergo stem cell transplant on day 0.

GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity.

After the completion of study treatment, patients are followed up for up to 30-100 days and then up to 2 years after transplant.

연구 유형

중재적

등록 (실제)

52

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • California
      • Duarte, California, 미국, 91010
        • City of Hope Medical Center

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

12년 이상 (어린이, 성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Documented informed consent of the participant and/or legally authorized representative

  • Willingness to be followed for the planned duration of the trial (2 years)

  • All subjects must have the ability to understand and the willingness to sign a written informed consent

  • Karnofsky performance status >= 60 per COH SOP

  • Patients must be undergoing allogeneic hematopoietic stem cell transplantation (alloHCT) for hematologic malignancies from matched related or matched unrelated donors with 8/8 (A, B, C, DRB 1) high resolution human leukocyte antigen (HLA) donor allele matching

  • Patients must be receiving a fractionated total body radiation (FTBI) based- myeloablative conditioning regimen; (acceptable conditioning regimens include total body irradiation [TBI] + cyclophosphamide or TBI + etoposide)

  • Ejection fraction measured by echocardiogram or multi gated acquisition scan (MUGA) > 50%

  • Diffusing capacity for carbon monoxide (DLCO) adjusted for hemoglobin or forced vital capacity (FVC) > 50% predicted

  • Total serum bilirubin < 2 times upper limit of normal

  • Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 x the upper normal limit

  • Alkaline phosphatase =< 2.5 x the upper normal limit

  • Measured creatinine clearance more than 60 mL/min

  • Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through 90 days after the last dose of protocol therapy

    • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)

Exclusion Criteria:

  • Failure of research participant to understand the basic elements of the protocol and/or the risks/benefits of participating in this pilot study. A legal guardian may substitute for the research participant
  • Research participants receiving any other investigational agents
  • Research participants with presence of other active malignancy within 2 years of study entry. Participants with history of prior malignancy treated with curative intent who achieved complete remission (CR) more than 2 years before study entry are eligible. This exclusion rule does not apply to non-melanoma skin tumors and in-situ cervical cancer
  • Research participants having any uncontrolled illness including ongoing or active infection. Research participants with known active hepatitis B or C infection; research participants who are human immunodeficiency virus (HIV) seropositive based on testing performed within 4 weeks of enrollment; research participants with any signs or symptoms of active infection, positive blood cultures, or radiological evidence of infections
  • Refusing to use contraception up to 90 days post-HCT
  • Pregnant and/or breast feeding if a female recipient
  • Lactose intolerance or intolerance to milk products
  • In the opinion of the principal investigator (PI), the participant has a condition that will preclude them from complying with study treatment

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 지지 요법
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Group A (conditioning, goat milk, transplant, prophylaxis)

CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.

HLZ: Patients receive human lysozyme goat milk PO TID on days -8 to 28 in the absence of disease progression or unacceptable toxicity.

TRANSPLANT: Patients undergo stem cell transplant on day 0.

GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity.

Given IV

다른 이름들:
  • 사이톡산
  • CTX
  • (-)-시클로포스파미드
  • 2H-1,3,2-옥사자포스포린, 2-[비스(2-클로로에틸)아미노]테트라하이드로-, 2-옥사이드, 일수화물
  • 칼록산
  • 시클로포스파미다
  • 시클로포스파마이드
  • 시클록살
  • 클라펜
  • CP 일수화물
  • CYCLO 셀
  • 사이클로블라스틴
  • 사이클로포스팜
  • 사이클로포스파미드 일수화물
  • 사이클로포스파미둠
  • 시클로포스판
  • 사이클로포스판
  • 시클로포스파늄
  • 사이클로스틴
  • 사이토포스판
  • 포스파세론
  • 제녹살
  • 제눅살
  • 레독시나
  • 미톡산
  • 네오사르
  • 리바이뮨
  • 실클로포스파미드
  • WR-138719

Given IV

다른 이름들:
  • 데메틸 에피포도필로톡신 에틸리딘 글루코사이드
  • 에펙
  • 라셋
  • 토포사르
  • 베페시드
  • 부사장 16
  • 부사장 16-213
  • VP-16
  • VP-16-213
  • VP16

Given PO

다른 이름들:
  • 라파뮨
  • AY 22989
  • 라파
  • 라파마이신
  • 실라 9268A
  • WY-090217

Undergo allo-HCT

다른 이름들:
  • 동종 조혈 세포 이식
  • HSC
  • 조혈모세포이식
  • 동종 줄기 세포 이식

Undergo FTBI

다른 이름들:
  • 분할 정위 방사선 요법

Given human lysozyme goat milk PO

Given IV

다른 이름들:
  • 성장인자, 재조합 인간 케라티노사이트
  • 케피밴스
  • 케라티노사이트 성장 인자, 재조합 인간
  • 재조합 인간 케라티노사이트 성장 인자
  • rhKGF
  • rhu 케라티노사이트 성장 인자

Given IV and PO

다른 이름들:
  • 프로그라프
  • 헤코리아
  • FK 506
  • 후지마이신
  • 프로토픽
활성 비교기: Group B (conditioning, transplant, prophylaxis)

CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2 per COH SOP, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.

TRANSPLANT: Patients undergo stem cell transplant on day 0.

GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity.

Given IV

다른 이름들:
  • 사이톡산
  • CTX
  • (-)-시클로포스파미드
  • 2H-1,3,2-옥사자포스포린, 2-[비스(2-클로로에틸)아미노]테트라하이드로-, 2-옥사이드, 일수화물
  • 칼록산
  • 시클로포스파미다
  • 시클로포스파마이드
  • 시클록살
  • 클라펜
  • CP 일수화물
  • CYCLO 셀
  • 사이클로블라스틴
  • 사이클로포스팜
  • 사이클로포스파미드 일수화물
  • 사이클로포스파미둠
  • 시클로포스판
  • 사이클로포스판
  • 시클로포스파늄
  • 사이클로스틴
  • 사이토포스판
  • 포스파세론
  • 제녹살
  • 제눅살
  • 레독시나
  • 미톡산
  • 네오사르
  • 리바이뮨
  • 실클로포스파미드
  • WR-138719

Given IV

다른 이름들:
  • 데메틸 에피포도필로톡신 에틸리딘 글루코사이드
  • 에펙
  • 라셋
  • 토포사르
  • 베페시드
  • 부사장 16
  • 부사장 16-213
  • VP-16
  • VP-16-213
  • VP16

Given PO

다른 이름들:
  • 라파뮨
  • AY 22989
  • 라파
  • 라파마이신
  • 실라 9268A
  • WY-090217

Undergo allo-HCT

다른 이름들:
  • 동종 조혈 세포 이식
  • HSC
  • 조혈모세포이식
  • 동종 줄기 세포 이식

Undergo FTBI

다른 이름들:
  • 분할 정위 방사선 요법

Given IV

다른 이름들:
  • 성장인자, 재조합 인간 케라티노사이트
  • 케피밴스
  • 케라티노사이트 성장 인자, 재조합 인간
  • 재조합 인간 케라티노사이트 성장 인자
  • rhKGF
  • rhu 케라티노사이트 성장 인자

Given IV and PO

다른 이름들:
  • 프로그라프
  • 헤코리아
  • FK 506
  • 후지마이신
  • 프로토픽

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Patients' ability to drink the specified daily amount of 750 ml human lysozyme goat milk (hLZ)
기간: from study initiation until up to 28 days post-transplant or until discharge, whoever comes first

In the safety lead-in phase, we are going to investigate if a patient can drink the daily amount of 750 ml of hLZ.. The actual volume of milk consumed per day will be measured using graduated cups and recorded on daily basis.

To calculate the average daily consumption, total volume of hLZ consumed by each patient for the whole inpatient stay will be divided by the total number of inpatient stay for that patient. Tolerable dose established based on the average daily hLZ consumption in the first 6 patients (safety lead-in) will be brought forward for additional study randomization.

from study initiation until up to 28 days post-transplant or until discharge, whoever comes first
Unacceptable toxicity
기간: Up to 28 days post-transplant or date of discharge

The modified Bearman Scale will be used to define unacceptable toxicity events. Unacceptable toxicity in a given patient is defined as either of the following that are considered at least possibly related to drinking hLZ milk: GI toxicity grade III or IV per Bearman scale or inability to consume hLZ milk for > 7 days.

Up to 28 days post-transplant or date of discharge
Adverse events
기간: Up to 100 days post-transplant

Incidence and severity of adverse events will be reported according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.03. Observed toxicities will be summarized in terms of type (organ affected or laboratory determination), severity, time of onset, duration, probable association with the study treatment and reversibility or outcome.

Up to 100 days post-transplant
Volume of hLZ consumed
기간: Up to 28 days post-transplant or date of discharge

Tolerability is defined as the ability to consume >= 150 ml/day over the treatment period.

Up to 28 days post-transplant or date of discharge

2차 결과 측정

결과 측정
측정값 설명
기간
Cumulative incidence (CI) of chronic graft versus host disease (GVHD)
기간: At 6 months

Chronic graft versus host disease is scored according to NIH Consensus Staging. The first day of chronic GvHD onset will be used to calculate confidence interval (CI) incidence curves, with relapse/death prior to onset considered competing events. CI of chronic GVHD will be estimated using the method described by Gooley et al (1999).

At 6 months
Cumulative incidence (CI) of chronic GVHD
기간: At 1 year

Chronic graft versus host disease is scored according to NIH Consensus Staging. The first day of chronic GvHD onset will be used to calculate CI incidence curves, with relapse/death prior to onset considered competing events. CI of chronic GVHD will be estimated using the method described by Gooley et al (1999).

At 1 year
Cumulative incidence (CI) of chronic GVHD
기간: At 2 years

Chronic graft versus host disease is scored according to NIH Consensus Staging. The first day of chronic GvHD onset will be used to calculate CI incidence curves, with relapse/death prior to onset considered competing events. CI of chronic GVHD will be estimated using the method described by Gooley et al (1999).

At 2 years
CI of non-relapse mortality (NRM)
기간: At 100 days

Non-relapse mortality (NRM) is defined as death occurring in a patient from causes other than relapse. NRM is measured from start of treatment until non-disease related death, or last follow-up, whichever comes first. The cumulative incidence of NRM will be calculated reflecting relapse as a competing risk. CI of NRM will be estimated using the method described by Gooley et al (1999).

At 100 days
CI of NRM
기간: At 1 year

Non-relapse mortality (NRM) is defined as death occurring in a patient from causes other than relapse. NRM is measured from start of treatment until non-disease related death, or last follow-up, whichever comes first. The cumulative incidence of NRM will be calculated reflecting relapse as a competing risk. CI of NRM will be estimated using the method described by Gooley et al (1999).

At 1 year
CI of NRM
기간: At 2 years

Non-relapse mortality (NRM) is defined as death occurring in a patient from causes other than relapse. NRM is measured from start of treatment until non-disease related death, or last follow-up, whichever comes first. The cumulative incidence of NRM will be calculated reflecting relapse as a competing risk. CI of NRM will be estimated using the method described by Gooley et al (1999).

At 2 years
CI of relapse/progression
기간: At 100 days

The event is relapse/progression. Time to this event is measured from start of treatment. Death without relapse/progression is considered a competing risk. Surviving patients with no history of relapse are censored at time of last follow-up. CI of relapse/progression will be estimated using the method described by Gooley et al (1999).

At 100 days
CI of relapse/progression
기간: At 1 year

The event is relapse/progression. Time to this event is measured from start of treatment. Death without relapse/progression is considered a competing risk. Surviving patients with no history of relapse are censored at time of last follow-up. CI of relapse/progression will be estimated using the method described by Gooley et al (1999).

At 1 year
CI of relapse/progression
기간: At 2 years

The event is relapse/progression. Time to this event is measured from start of treatment. Death without relapse/progression is considered a competing risk. Surviving patients with no history of relapse are censored at time of last follow-up. CI of relapse/progression will be estimated using the method described by Gooley et al (1999).

At 2 years
Gut microbiome diversity
기간: Day - 8 +/- 3, day 0, day +7, day +14, day +21, day +28

Gut microbiome diversity will be assessed by the Simpson Index and compared between hLZ-treated/untreated patients. Association between treatment and gut microbial diversity will be assessed by Fisher's Exact test.

Day - 8 +/- 3, day 0, day +7, day +14, day +21, day +28
CI of acute graft versus host disease (aGVHD)
기간: At 100 days

Acute graft versus host disease will be graded according to the Consensus Grading. The first day of acute GvHD onset at a certain grade will be used to calculate cumulative incidence curves for that GvHD grade; relapse/death prior to onset will be considered competing events. CI of aGVHD will be estimated using the method described by Gooley et al (1999). Association between gut microbial diversity (inverse Simpson index: high [> 4], intermediate [2-4], and low [< 2]) or treatment and CI of aGVHD will be assessed by Gray's test.

At 100 days
Incidence of bloodstream infections
기간: Up to 100 days

Incidence of bloodstream infections and infectious enterocolitis will be evaluated and a preliminary estimate of the association between gut microbiome diversity and bloodstream infections will be obtained. Association between gut microbial diversity (inverse Simpson index: high [> 4], intermediate [2-4], and low [< 2]) or treatment and CI of bloodstream infections will be assessed by Gray's test.

Up to 100 days
Overall survival (OS)
기간: At 100 days

Patients are considered a failure for this endpoint if they die, regardless of cause. The time to this event is the time from start of treatment until death, or last follow-up, whichever comes first. OS will be estimated using the product-limit method of Kaplan and Meier.

At 100 days
Overall survival (OS)
기간: At 1 year

Patients are considered a failure for this endpoint if they die, regardless of cause. The time to this event is the time from start of treatment until death, or last follow-up, whichever comes first. OS will be estimated using the product-limit method of Kaplan and Meier.

At 1 year
Overall survival (OS)
기간: At 2 years

Patients are considered a failure for this endpoint if they die, regardless of cause. The time to this event is the time from start of treatment until death, or last follow-up, whichever comes first. OS will be estimated using the product-limit method of Kaplan and Meier.

At 2 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Karamjeet S Sandhu, City of Hope Medical Center

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 4월 30일

기본 완료 (실제)

2025년 12월 29일

연구 완료 (추정된)

2027년 3월 23일

연구 등록 날짜

최초 제출

2019년 10월 14일

QC 기준을 충족하는 최초 제출

2019년 11월 22일

처음 게시됨 (실제)

2019년 11월 26일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 9일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다